Browse articles from EyeWorld.org related to the retina. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Topline data from Phase 3 trial of presbyopia-correcting drop
➤ FDA gives 510(K) approval to updated neuromodulation therapy for increased tear production
➤ Enrollment complete for Phase 3 trial of reproxalap
➤ DME trial to focus on underrepresented patient populations
➤ BLA submitted to FDA for wet AMD therapy
➤ Companies collaborate to further develop gene therapy for retinal disease
➤ ASCRS news and events
➤ Nerve growth factor being studied as a possible treatment for Sjogren’s-related dry eye
➤ Investigational RNA therapy doesn’t meet primary endpoint
➤ Phase 1 clinical trial for bioerodible, sustained anti-VEGF delivery
➤ Positive interim data for diabetic retinopathy treatment
➤ Positive results in trial for high-dose aflibercept
➤ Additional Phase 3 trial data for Beovu in DME
➤ ASCRS news and events
➤ Controversies in cataract and refractive surgery
➤ Hot topics in ophthalmology
➤ Ophthalmic Premier League
➤ Management of retinal vasculitis
➤ Discussion of same-day bilateral cataract surgery ➤ DMEK in complex eyes ➤ Do’s and Don’ts of corneal crosslinking for keratoconus ➤ Reconstruction of the ocular surface ➤ Late-breaking developments in retina ➤ Long-term follow-up with port delivery system of ranibizumab for AMD
➤ FDA approves first prescription eye drop for presbyopia treatment
➤ Primary endpoint reached in Phase 2 trial for dry eye disease drug
➤ New type of retinal nerve cell discovered
➤ Companies enter collaboration to develop an oral DME, wet AMD treatment
➤ iCare USA acquires remote patient-monitoring tech company
➤ ASCRS news and events
➤ FDA approves nasal spray for dry eye
➤ Survey: 70% of adults don’t plan on receiving an eye exam this year
➤ Positive results in Phase 3 study for Acanthamoeba keratitis treatment
➤ Research on first-in-class therapy for retinal degenerative disease
➤ ASCRS news and events
➤ Survey: Patient perspectives on presbyopia
➤ Study: Wearable visual field testing device correlates with standard testing, offers efficiency
➤ Endpoints not met in blepharitis drug trial
➤ Retinal cell protection observed in non-clinical model with investigational IOP-lowering drug
➤ Extension study of investigational wet AMD therapy shows reduction of injection burden
➤ 12-month safety data reported from Phase 3 bevacizumab trial
➤ ASCRS news and events
➤ Patient enrollment complete for Phase 2 trial of DED drug candidate
➤ New investigational drug candidates for cornea, glaucoma, and wet AMD
➤ IND filed for glaucoma drug candidate
➤ Collaboration for one-time treatment of several retinal conditions
➤ ASCRS news and events
➤ Phase 4 trial for thyroid eye disease begins
➤ Glaukos submits supplemental pre-market approval application for iStent infinite
➤ Gene therapy for Leber hereditary optic neuropathy receives milestone designation in U.K.
➤ ASCRS news and events
➤ Phase 2 results for cream to treat signs, symptoms of dry eye associated with MGD ➤ Studies support clinical value of ultra-widefield and SS-OCT imaging device ➤ New combination treatment shows promise for metastatic uveal melanoma ➤ ASCRS news and events
